Reports
Reports
Sale
The global particle therapy market size was valued at USD 747.1 million in 2023, driven by increasing advancements and research studies to find better cancer treatment radiation therapies without damaging nearby tissues. The market size is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032 to achieve a value of USD 1531.1 million by 2032.
Particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that uses charged particles such as protons or heavy ions to target and destroy cancer cells. Particle therapy delivers highly precise and controlled doses of radiation to tumours while minimizing damage to surrounding healthy tissues. Particle therapy is proven to show promising results in the treatment of certain cancers but it may not be considered for all types of cancer and patients.
The growth of the market is driven by increased research studies by scientists and doctors to provide better treatment options for cancer patients. For example, in a randomized clinical trial, researchers have discovered evidence promising shorter treatment time for breast cancer patients. In this trial, two separate dosing schedules of pencil-beam scanning proton therapy were compared. This therapy is known to be the most advanced type of proton therapy which is precise in targeting cancer cells without damaging healthy tissue resulting in reduced risk of side effects.
The particle therapy market demand is also driven by the increasing awareness among pharmaceutical companies that are looking to develop new and effective treatment therapy options for patients suffering from cancers and tumours all over the world. These companies are trying to develop proton therapies that are enabled with extreme precision when it comes to targeting cancer cells. For example, Terapet, a Geneva-based CERN start-up recently announced that they have ended up raising 2.3 million CHF (Swiss Francs) for the development of the next generation of nuclear imaging products. Terapet’s novel technology has the potential to make nuclear medicine imaging more accessible for every patient in the future. Terapet is targeted towards ensuring the right dose for every patient, every time. The company is also to exhibit its first product to the particle therapy community at PTCOG 2023 in Madrid.
The increased awareness and adoption of particle therapies are further escalating the global particle therapy market growth. For example, the inauguration of the much-awaited proton beam therapy facility in India took place earlier this year in Mumbai. This facility is the first in a public setup in the country. The government is set to provide this cutting-edge technology to 60% of the patients for free and the other 40% would pay a subsidized amount. The availability of such treatment options plays a huge role in reducing the mortality rate due to certain medical conditions such as cancer.
Additionally, Hitachi has successfully delivered a heavy ion therapy system to Taipei Veterans General Hospital situated in Taiwan and the system has also started operating as well. This is the first-ever heavy ion therapy system delivery made by Hitachi, outside of Japan.
Hitachi is committed to enhancing the quality of life for cancer patients in Taiwan and promoting patient-centered treatment. The company will persist in its efforts to expand the global reach of its particle therapy system business, thereby advancing the field of minimally invasive cancer treatments. Having successfully treated more than 85,000 patients to date, Hitachi offers a range of high-performance products and services. These offerings range from the specialized compact Proton single-room solution to the versatile Hybrid System, which combines the capabilities of proton and carbon therapy to provide even greater value.
Market Breakup by Therapy Type
Market Breakup by Cancer Type
Market Breakup by Applications
Market Breakup by Region
The global market is experiencing a significant rise in adoption, awareness, and demand. This rising awareness has led to a surge in clinical studies aimed at discovering the full potential of particle therapy for cancer and tumour treatment. Moreover, the increasing reliability of this treatment method, backed by positive outcomes, has further bolstered its popularity contributing to the global particle therapy market growth. According to data from the American Cancer Society, the United States is expected to witness over 1.9 million new cancer cases in 2023, with cancer ranking as the second leading cause of death and projected to account for approximately 609,820 deaths, equivalent to 1,670 lives lost each day.
Geographically, North America is currently leading the regional market, and this dominance is expected to persist throughout the forecast period. Factors contributing to regional market dominance include the presence of a well-established healthcare system, a growing geriatric population, and a rising number of healthcare facilities offering proton therapy favorable reimbursement policies.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapy Type |
|
Breakup by Cancer Type |
|
Breakup by Applications |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Particle Therapy Market Overview
3.1 Global Particle Therapy Market Historical Value (2017-2023)
3.2 Global Particle Therapy Market Forecast Value (2024-2032)
4 Global Particle Therapy Market Landscape
4.1 Global Particle Therapy: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Particle Therapy: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global Particle Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Particle Therapy Market Segmentation
6.1 Global Particle Therapy Market by Therapy Type
6.1.1 Market Overview
6.1.2 Proton Therapy
6.1.3 Heavy Ion Therapy
6.1.4 Fast-Neutron Therapy
6.2 Global Particle Therapy Market by Cancer Type
6.2.1 Market Overview
6.2.2 Prostate Cancer
6.2.3 Breast Cancer
6.2.4 Lung Cancer
6.2.5 Head and Neck Cancer
6.2.6 Other Cancers
6.3 Global Particle Therapy Market by Applications
6.3.1 Market Overview
6.3.2 Food and Beverage
6.3.3 Nutraceuticals and Pharmaceuticals
6.3.4 Cosmetics and Personal Care
6.4 Global Particle Therapy Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Particle Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Particle Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Particle Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Particle Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Particle Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Advanced Oncotherapy
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 IBA Worldwide
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Accuray Incorporated
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Brainlab
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Elekta AB
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Panacea
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Shinva Medical Instrument Co. Ltd
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 xstrahl
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Danfysik A/S
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Hitachi Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 747.1 million in 2023, driven by increased awareness about the benefits of the therapy.
The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032 and is likely to reach a market value of USD 1531.1 million by 2032.
The increasing geriatric population, coupled with increased adoption of radiation therapies to treat cancer, is a major factor driving the market growth.
The increasing interest of big pharma or MedTech companies in the development of targeted particle therapies to treat cancer and tumours is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Different therapies in the market include proton therapy, heavy ion therapy, and fast-neutron therapy.
Types of cancer include prostate cancer, breast cancer, lung cancer, head and neck cancer, among other cancers.
They find wide applications in food and beverage, nutraceuticals and pharmaceuticals, and cosmetics and personal care.
Key players involved in the market are Advanced Oncotherapy, IBA Worldwide, Accuray Incorporated, Brainlab, Elekta AB, Panacea, Shinva Medical Instrument Co. Ltd, xstrahl, Hitachi Ltd., and Danfysik A/S.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.